Ip Share Discussion Threads

[safman] 10/2/2004 17:57

i'm well aware of that as well.. more than one institution... potentially an excellent stock.. if u r into technology..look at RFIDs .. stock ticker INN...have added INN..and add this soon...saw this initially at 3.40p...

[charlie100] 10/2/2004 17:46

what a lovely quiet thread, hear lots of institutions bidding for this one, may all be puff, but feels good so far

[mclellan] 02/2/2004 14:52

And going up in value,too!

[charlie100] 15/1/2004 09:08

Here is some more stuff from the company......Not sure of the date of publication...............

Creating value from intellectual assets

Introduction

IP2IPO creates value from intellectual property by entering into partnerships with UK Universities. UK universities generate some of the best science and engineering in the world and IP2IPO is an exciting new vehicle for unlocking the commercial potential of this research.

Oxford

In our first partnership with the University of Oxford, we invested £20m to acquire an interest in all intellectual property commercialised from the chemistry department until 2015. IP2IPO's interest under the partnership is a significant one – 50% of the university's equity interest in all chemistry department spinout companies and 50% of the university's entitlement to licence fees and royalty income derived from chemistry department intellectual property.
Southampton

In March 2002, we entered into a second university partnership with the University of Southampton.

Under our second partnership, IP2IPO has made two commitments: (1) to supply technology transfer expertise and resource to the complement the University's existing capabilities; (2) to invest £5m by way of seed finance in University of Southampton spinout companies. In addition to the equity stakes in Southampton spinouts that IP2IPO receives as a result of its seed capital investments, IP2IPO also receives a 20% interest in the University's share of equity in each spinout company until 2025.

Both IP2IPO's partnerships are premised on long-term mutual interest and each partnership has been structured to ensure that both sides have a vested interest in its success.
Forming a university partnership is just the first step. Our goal is to maximise the value of our intellectual property assets, for the benefit of IP2IPO's shareholders and our partners. In order to do so, IP2IPO has built a dedicated and experienced team for the purposes of:

· Identifying commercially exciting intellectual property developed by its partners
· Building business concepts around these promising pieces of intellectual property
· Providing hands-on support to our partners to turn the business concepts into companies
· Securing high quality, experienced management for each spinout company
· Creating a financial channel for the spinout: i.e. ensuring investment support
· Providing on-going strategic and commercial advice to the spinout
· Identifying appropriate exit strategies
Oxford Chemistry

The University of Oxford's chemistry department is immensely prestigious. It is the largest chemistry department in the western world employing 550 researchers in 70 research groups. In the 5-yearly review of research standards in the UK the department was awarded the highest possible grade and the pre-eminence of its research is reflected in the 10 Nobel prizes that have been awarded to members of the department. The department includes 33 full professors, some of whom (Sir Jack Baldwin, Professor Steve Davies, Professor Chris Schofield) are leading advisers to the pharmaceutical industry.

The department has an enviable track record for entrepreneurship. Successful spinouts from the department include Oxford Molecular, Medisense (acquired by Abbot labs for over $800m), Oxford Asymmetry (acquired by Evotec for over £300m) and Oxford Biosensors.

Chemistry is a science which underpins many branches of technology from pharmaceuticals to displays, from detergents to medical implants. In physical chemistry, the department's traditional strengths lie in electrochemistry (including fuel cell research), novel applications for lasers and sensors and novel materials (including nano-materials and opto-electronic materials). In organic chemistry, the focus of the department is on the synthesis of new drug like molecules at higher speeds and higher yields and the design of new molecules with novel electrical or optical properties. The department also hosts two internationally renown facilities: the Chemical Crystallography Centre which supports fundamental research into the identification of novel therapeutic targets and the Centre for Computational Drug Design which uses high speed computation to discover novel drugs. In addition, the department is one of the world's leading centres for molecular science and has extensive expertise in the structure, function and activity of proteins – a major area of therapeutic interest.

end of company stuff......

There is more, but this gives the reader a flavour of the operations/activities, high risk stuff investing here, very interesting never the less.

[assagai] 11/1/2004 09:52

As a pure momentum play this is looking very beefy right now - someone knows something that's for sure!.

[charlie100] 05/1/2004 16:09

This is a new thread, has there does'nt seem to be any coverage on this company.

IP2IPOhas been a entrant in the last 6 months, having been floated/sold off by Evolution. I think it is a good story, that needs a thread, to build discussion on.

It was written up in Express over the new year, (talk of several deals in the first quarter 2004).

I bought some today and will watch with interest, and other views?